Presentation is loading. Please wait.

Presentation is loading. Please wait.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Published byQuentin Morrison Modified over 6 years ago

Similar presentations

Presentation on theme: "Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro"— Presentation transcript:

1 Nat. Rev. Gastroenterol. Hepatol. doi:10.1038/nrgastro.2016.50
Figure 1 Current treatment algorithm for patients with typical GERD symptoms Figure 1 | Current treatment algorithm for patients with typical GERD symptoms. Investigation of patients with rGERD symptoms is centred around multichannel intraluminal impedance (MII)–pH monitoring. *Before rGERD can be considered, one should ensure that the PPI regimen is adequately dosed and timed, that patient compliance with the regimen is confirmed, and that symptoms are typical of GERD (heartburn and/or regurgitation) and are not located in the epigastrium (dyspepsia) or in the throat area. rGERD, refractory GERD. Scarpellini, E. et al. (2016) Management of refractory typical GERD symptoms Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Download ppt "Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro"

Similar presentations

Determinants of gastro-oesophageal reflux perception in patients with persistent symptoms despite proton pump inhibitors F Zerbib, A Duriez, S Roman, M.

Determinants of gastro-oesophageal reflux perception in patients with persistent symptoms despite proton pump inhibitors F Zerbib, A Duriez, S Roman, M.
Figure 3 Low-grade inflammation in FGID

Figure 3 Low-grade inflammation in FGID
Figure 2 Enteroids can model transport physiology

Figure 2 Enteroids can model transport physiology
Figure 1 Imaging of a depressed intramucosal carcinoma

Figure 1 Imaging of a depressed intramucosal carcinoma
Figure 4 Activation of clopidogrel via cytochrome P450

Figure 4 Activation of clopidogrel via cytochrome P450
Figure 5 Therapeutic paradigms for interfering with the brain–gut axis

Figure 5 Therapeutic paradigms for interfering with the brain–gut axis
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 7 Treatment algorithm for perianal fistulizing disease

Figure 7 Treatment algorithm for perianal fistulizing disease
Figure 1 Patients cured of HCV infection

Figure 1 Patients cured of HCV infection
Figure 2 A stage-based approach to the treatment of NAFLD

Figure 2 A stage-based approach to the treatment of NAFLD
Figure 5 Lipid droplet consumption

Figure 5 Lipid droplet consumption
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 1 Worldwide incidence of CCA

Figure 1 Worldwide incidence of CCA
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 1 Biosimilar development process

Figure 1 Biosimilar development process
Michael F. Vaezi, David Katzka, Frank Zerbib 

Michael F. Vaezi, David Katzka, Frank Zerbib 
Figure 3 Algorithm from working group describing

Figure 3 Algorithm from working group describing
Figure 2 Effect of PPIs on gastric physiology

Figure 2 Effect of PPIs on gastric physiology

Similar presentations

Ads by Google